News Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
2.27 ^USD	-5.81%		-22.79%	+28.25%

Apr. 09	Piper Sandler Initiates Taysha Gene Therapies at Overweight Rating With $9 Price Target	MT
Mar. 21	Chardan Adjusts PT on Taysha Gene Therapies to $7 From $5 as Gene Therapy for Rett Syndrome Shows 'Sustained Benefit', Keeps Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Initiates Taysha Gene Therapies at Overweight Rating With $9 Price Target	Apr. 09	MT
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Apr. 05	AQ
Chardan Adjusts PT on Taysha Gene Therapies to $7 From $5 as Gene Therapy for Rett Syndrome Shows 'Sustained Benefit', Keeps Buy Rating	Mar. 21	MT
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply	Mar. 20	MT
US Futures Flat in Wednesday's Premarket as Investors Await Fed's Interest Rate Decision	Mar. 20	MT
Top Premarket Gainers	Mar. 20	MT
Needham Adjusts Taysha Gene Therapies Price Target to $7 From $5, Maintains Buy Rating	Mar. 20	MT
Taysha Gene Therapies Surges 26% Premarket After Full-Year 2023 Results Show Narrowing Net Loss, Surging Revenue	Mar. 20	MT
North American Morning Briefing : Markets on Hold as Fed Decision Nears	Mar. 20	DJ
Transcript : Taysha Gene Therapies, Inc., 2023 Earnings Call, Mar 19, 2024	Mar. 19
Taysha Gene Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates	Mar. 19	AQ
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19	Mar. 14	AQ
Taysha Gene Therapies : March 2024 Corporate Presentation	Mar. 08	PU
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Mar. 01	AQ
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome	Feb. 29	AQ
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs	Feb. 15	AQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Feb. 02	AQ
Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference	Jan. 22	AQ
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome	Jan. 10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Summary

Filters